R Wendel Naumann (Wendel Naumann)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Chemotherapy Induced

Top Venues

Journal of gynecologic oncology

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

R Wendel Naumann
The SHAPE trial: is good is good enough? Journal of gynecologic oncology 35 (4) (2024)
R Wendel Naumann
The SHAPE trial: is good is good enough? Journal of gynecologic oncology 35 (4) (2024)
R Wendel Naumann
The SHAPE trial: is good is good enough? Journal of gynecologic oncology 35 (4) (2024)
R Wendel Naumann
The SHAPE trial: is good is good enough? Journal of gynecologic oncology 35 (4) (2024)
R Wendel Naumann
The SHAPE trial: is good is good enough? Journal of gynecologic oncology (2024)
Khrystyna Levytska, Savannah R Pena, Jubilee Brown, Ziqing Yu, Meghan K Wally, Joseph R Hsu, Rachel B Seymour, R Wendel Naumann, null null
Opioid and benzodiazepine use in gynecologic oncology patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Carol J Farhangfar, Gregory T Scarola, Victoria A Morris, Farhang Farhangfar, Kathryn Dumas, James Symanowski, Jimmy J Hwang, Kathryn F Mileham, Daniel R Carrizosa, R Wendel Naumann, Chad Livasy, Edward S Kim, Derek Raghavan
Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients. JCO clinical cancer informatics 6 (2022)
Siqing Fu, Bradley R Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R Wendel Naumann, Robert M Wenham, Rafael D Rosengarten, Laura Benjamin, Erika Paige Hamilton, Kathleen M Moore
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)